Treatment of mitochondrial disorders

European Journal of Paediatric Neurology

Volumn 14, Issue 1, 2010, Pages 29-44

  Finsterer, Josef ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Brain; Cerebrum; Encephalomyopathy; Mitochondrial cytopathy; Mitochondriopathy; Multi system disease; Oxidative phosphorylation; Respiratory chain; Spinal cord

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; ASPARTIC ACID; BARBITURIC ACID DERIVATIVE; CARNITINE; CISAPRIDE; CITRIC ACID; COPPER; CORTICOSTEROID; CREATINE; DICHLOROACETIC ACID; DOMPERIDONE; FOLIC ACID; HALOTHANE; HYDROCORTISONE; IDEBENONE; IRON; ISOFLURANE; MELATONIN; NORPHENAZONE; POTASSIUM; PYRIDOXINE; RIBOFLAVIN; SEVOFLURANE; SODIUM; SUCCINIC ACID; THIAMINE; UBIQUINONE; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; ALPERS DISEASE; AMINOACIDURIA; ANEMIA; ANTICOAGULATION; ARTERIAL GAS; ARTIFICIAL HEART PACEMAKER; BARTH SYNDROME; BLOOD TRANSFUSION; CARBOHYDRATE DIET; CHOLESTASIS; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DEFIBRILLATOR; DEMENTIA; DIABETES MELLITUS; DIET THERAPY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CONTRAINDICATION; DRUG WITHDRAWAL; DYSARTHRIA; DYSTONIA; EPILEPSY; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE THERAPY; GENETIC ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; GERM LINE GENE THERAPY; GROWTH RETARDATION; HAPLOTYPE; HEADACHE; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTROPHIC CARDIOMYOPATHY; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INVASIVE PROCEDURE; KEARNS SAYRE SYNDROME; KETOGENIC DIET; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; LEIGH DISEASE; LEUKOENCEPHALOPATHY; LIPID DIET; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRION; MNGIE SYNDROME; MUSCLE STRENGTH; NARP SYNDROME; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OPHTHALMOPLEGIA; PARKINSONISM; PEARSON SYNDROME; PHENOTYPE; PHYSIOTHERAPY; POINT MUTATION; PRIORITY JOURNAL; REVIEW; SIDEROBLASTIC ANEMIA; STEM CELL TRANSPLANTATION; STENT; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; X LINKED SIDEROBLASTIC ANEMIA;

DNA, MITOCHONDRIAL; DRUG THERAPY; GENE THERAPY; HUMANS; MITOCHONDRIAL DISEASES; MUTATION; STEM CELL TRANSPLANTATION;

EID: 71649095031     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2009.07.005     Document Type: Review

References (158)

1. DiMauro S., and Schon E.A. Mitochondrial disorders in the nervous system. Annu Rev Neurosci 31 (2008) 91-123
2. Zeviani M., and Di Donato S. Mitochondrial disorders. Brain 127 (2004) 2153-2172
3. Montirosso R., Brambilla D., Felisari G., Sclaunich F., Filipponi E., Pozzoli U., et al. Electrophysiological analysis of cognitive slowing in subjects with mitochondrial encephalomyopathy. J Neurol Sci 194 (2002) 3-9
4. Longo N. Mitochondrial encephalopathy. Neurol Clin 21 (2003) 817-831
5. Finsterer J. Overview on visceral manifestations of mitochondrial disorders. Neth J Med 64 (2006) 61-71
6. Finsterer J., Jarius C., Eichberger H., et al. Phenotype variability in 130 adult patients with respiratory chain disorders. J Inherit Metab Dis 24 (2001) 560-576
7. Leonard J.V., and Schapira A.H.V. Mitochondrial respiratory chain disorders I: mitochondrial DNA defects. Lancet 355 (2000) 299-304
8. Kyriakouli D.S., Boesch P., Taylor R.W., and Lightowlers R.N. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 15 (2008) 1017-1023
9. Zeviani M., and Carelli V. Mitochondrial disorders. Curr Opin Neurol 16 (2003) 585-594
10. Schon E.A. Appendix. In: DiMauro S., Hirano M., and Schon E.A. (Eds). Mitochondrial medicine (2006), Informa Healthcare, London 329-336
11. Limongelli A., Schaefer J., Jackson S., Invernizzi F., Kirino Y., Suzuki T., et al. Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome. J Med Genet 41 (2004) 342-349
12. Zeviani M., Tiranti V., D'Adamo P., et al. Nuclear genes in mitochondrial disorders. Eur J Neurol 11 Suppl. 2 (2004) 5
13. Finsterer J, Harbo HF, Baets J, van Broeckhoven C, Di Donato S, Fontaine B, et al. EFNS guidelines on the molecular diagnosis of neurogenetic disorders (II). Mitochondrial disorders. Eur J Neurol 2009; (in press).
14. Campos Y., Martín M.A., Rubio J.C., Gutiérrez del Olmo M.C., Cabello A., and Arenas J. Bilateral striatal necrosis and MELAS associated with a new T3308C mutation in the mitochondrial ND1 gene. Biochem Biophys Res Commun 238 (1997) 323-325
15. Prietsch V., Lindner M., Zschocke J., Nyhan W.L., and Hoffmann G.F. Emergency management of inherited metabolic diseases. J Inherit Metab Dis 25 (2002) 531-546
16. McFarland R., Taylor R.W., and Turnbull D.M. The neurology of mitochondrial DNA disease. Lancet Neurol 1 (2002) 343-351
17. DiMauro S., and Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 27 (2007) 125-137
18. Invernizzi F., Varanese S., Thomas A., Carrara F., Onofrj M., and Zeviani M. Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism. Neuromuscul Disord 18 (2008) 460-464
19. Ben Smail D., Jacq C., Denys P., and Bussel B. Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. Mov Disord 20 (2005) 758-759
20. Chan Y.C. Aripiprazole treatment for psychosis associated with Friedreich's ataxia. Gen Hosp Psychiatry 27 (2005) 372
21. Ahmad A., Kahler S.G., Kishnani P.S., Artigas-Lopez M., Pappu A.S., Steiner R., et al. Treatment of pyruvate carboxylase deficiency with high doses of citrate and aspartate. Am J Med Genet 87 (1999) 331-338
22. Frezzotti P., and Frezzotti R. Primary open angle glaucoma in a case of mitochondrial encephalomyopathy (Kearns-Sayre syndrome). Eur J Ophthalmol 15 (2005) 809-810
23. Zaffanello M., and Zamboni G. Therapeutic approach in a case of Pearson's syndrome. Minerva Pediatr 57 (2005) 143-146
24. DiMauro S., Hirano M., and Schon E.A. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 34 (2006) 265-283
25. Jou M.J., Peng T.I., Yu P.Z., Jou S.B., Reiter R.J., Chen J.Y., et al. Melatonin protects against common deletion of mitochondrial DNA-augmented mitochondrial oxidative stress and apoptosis. J Pineal Res 43 (2007) 389-403
26. León J., Acuña-Castroviejo D., Escames G., Tan D.X., and Reiter R.J. Melatonin mitigates mitochondrial malfunction. J Pineal Res 38 (2005) 1-9
27. Sheu S.S., Nauduri D., and Anders M.W. Targeting antioxidants to mitochondria: a new therapeutic direction. Biochim Biophys Acta 1762 (2006) 256-265
28. Lodi R., Tonon C., Calabrese V., and Schapira A.H. Friedreich's ataxia: from disease mechanisms to therapeutic interventions. Antioxid Redox Signal 8 (2006) 438-443
29. Artuch R., Aracil A., Mas A., et al. Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics 33 (2002) 190-193
30. Napolitano A., Salvetti S., Vista M., Lombardi V., Siciliano G., and Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol Sci 21 Suppl. 5 (2000) S981-S982
31. Barisic N., Bernert G., Ipsiroglu O., et al. Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33 (2002) 157-161
32. James A.M., Smith R.A., and Murphy M.P. Antioxidant and prooxidant properties of mitochondrial coenzyme Q. Arch Biochem Biophys 423 (2004) 47-56
33. Briere J.J., Schlemmer D., Chretien D., and Rustin P. Quinone analogues regulate mitochondrial substrate competitive oxidation. Biochem Biophys Res Commun 316 (2004) 1138-1142
34. Bonakdar R.A., and Guarneri E. Coenzyme Q10. Am Fam Physician 72 (2005) 1065-1070
35. López L.C., Schuelke M., Quinzii C.M., Kanki T., Rodenburg R.J., Naini A., et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 79 (2006) 1125-1129
36. Aure K., Benoist J.F., Ogier de Baulny H., Romero N.B., Rigal O., and Lombes A. Progression despite replacement of a myopathic form of coenzyme Q10 defect. Neurology 24 63 (2004) 727-729
37. DiMauro S., and Gurgel-Giannetti J. The expanding phenotype of mitochondrial myopathy. Curr Opin Neurol 18 (2005) 538-542
38. Littarru G.P., and Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care 8 (2005) 641-646
39. Montero R., Pineda M., Aracil A., Vilaseca M.A., Briones P., Sánchez-Alcázar J.A., et al. Clinical, biochemical and molecular aspects of cerebellar ataxia and coenzyme Q10 deficiency. Cerebellum 6 (2007) 118-122
40. Salviati L., Sacconi S., Murer L., Zacchello G., Franceschini L., Laverda A.M., et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 65 (2005) 606-608
41. Choi C., Sunwoo I.N., Kim H.S., and Kim D.I. Transient improvement of pyruvate metabolism after coenzyme Q therapy in Kearns-Sayre syndrome: MRS study. Yonsei Med J 41 (2000) 676-679
42. Van Maldergem L., Trijbels F., DiMauro S., et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 52 (2002) 750-754
43. Cooper J.M., and Schapira A.H. Friedreich's ataxia: disease mechanisms, antioxidant and coenzyme Q10 therapy. Biofactors 18 (2003) 163-171
44. Schols L., Meyer C., Schmid G., Wilhelms I., and Przuntek H. Therapeutic strategies in Friedreich's ataxia. J Neural Transm Suppl 68 (2004) 135-145
45. Hart P.E., Lodi R., Rajagopalan B., Bradley J.L., Crilley J.G., Turner C., et al. Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch Neurol 62 (2005) 621-626
46. Chen R.S., Huang C.C., and Chu N.S. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. Eur Neurol 37 (1997) 212-218
47. Bresolin N., Bet L., Binda A., Moggio M., Comi G., Nador F., et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 38 (1988) 892-899
48. Maeda K., Tatsumi M., Tahara M., Murata Y., Kawai H., and Yasuda H. A case of stroke-like episode of MELAS of which progressive spread would be prevented by edaravone. Rinsho Shinkeigaku 45 (2005) 416-421
49. Langsjoen P.H., Langsjoen A., Willis R., and Folkers K. Treatment of hypertrophic cardiomyopathy with coenzyme Q10. Mol Aspects Med 18 Suppl. (1997) S145-S151
50. Lodi R., Rajagopalan B., Bradley J.L., Taylor D.J., Crilley J.G., Hart P.E., et al. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives. Free Radic Res 36 (2002) 461-466
51. Mashima Y., Kigasawa K., Wakakura M., and Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?. J Neuroophthalmol 20 (2000) 166-170
52. Pineda M., Arpa J., Montero R., Aracil A., Domínguez F., Galván M., et al. Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12 (2008) 470-475
53. Di Prospero N.A., Baker A., Jeffries N., and Fischbeck K.H. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol 6 (2007) 878-886
54. Barnils N., Mesa E., Muñoz S., Ferrer-Artola A., and Arruga J. Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy. Arch Soc Esp Oftalmol 82 (2007) 377-380
55. Marriage B., Clandinin M.T., and Glerum D.M. Nutritional cofactor treatment in mitochondrial disorders. J Am Diet Assoc 103 (2003) 1029-1038
56. de la Asunción J.G., Del Olmo M.L., Gómez-Cambronero L.G., Sastre J., Pallardó F.V., and Viña J. AZT induces oxidative damage to cardiac mitochondria: protective effect of vitamins C and E. Life Sci 76 (2004) 47-56
57. Berthiaume J.M., Oliveira P.J., Fariss M.W., and Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction. Cardiovasc Toxicol 5 (2005) 257-267
58. Smith A.R., Shenvi S.V., Widlansky M., Suh J.H., and Hagen T.M. Lipoic acid as a potential therapy for chronic diseases associated with oxidative stress. Curr Med Chem 11 (2004) 1135-1146
59. Moini H., Packer L., and Saris N.E. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Pharmacol 182 (2002) 84-90
60. Rossi F.H., Okun M., Yachnis A., Quisling R., and Triggs W.J. Corticosteroid treatment of mitochondrial encephalomyopathies. Neurologist 8 (2002) 313-315
61. Hsu C.C., Chuang Y.H., Tsai J.L., Jong H.J., Shen Y.Y., Huang H.L., et al. CPEO and carnitine deficiency overlapping in MELAS syndrome. Acta Neurol Scand 92 (1995) 252-255
62. Gubbay S.S., Hankey G.J., Tan N.T., and Fry J.M. Mitochondrial encephalomyopathy with corticosteroid dependence. Med J Aust 151 (1989) 100-103
63. Barak Y., Arnon S., Wolach B., Raz Y., Ashkenasi A., Glick B., et al. MELAS syndrome: peripheral neuropathy and cytochrome C-oxidase deficiency: a case report and review of the literature. Isr J Med Sci 31 (1995) 224-229
64. Kubota M., Sakakihara Y., Mori M., Yamagata T., and Momoi-Yoshida M. Beneficial effect of L-arginine for stroke-like episode in MELAS. Brain Dev 26 (2004) 481-483
65. Momtchilova M., Pelosse B., Saliba M., Abdiche G., Doummar D., Laroche L., et al. Recurrent visual loss in Leber hereditary optic neuropathy: a case report. J Fr Ophtalmol 31 (2008) 409-415
66. Letuve S., Druilhe A., Grandsaigne M., Aubier M., and Pretolani M. Critical role of mitochondria, but not caspases, during glucocorticosteroid-induced human eosinophil apoptosis. Am J Respir Cell Mol Biol 26 (2002) 565-571
67. Finsterer J. Mitochondriopathy mimicking amyotrophic lateral sclerosis. Neurologist 9 (2003) 45-48
68. Kc S., Cárcamo J.M., and Golde D.W. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J 19 (2005) 1657-1667
69. Martínez-Cruz F., Osuna C., and Guerrero J.M. Mitochondrial damage induced by fetal hyperphenylalaninemia in the rat brain and liver: its prevention by melatonin, vitamin E, and vitamin C. Neurosci Lett 392 (2006) 1-4
70. Ghelli A., Porcelli A.M., Zanna C., Martinuzzi A., Carelli V., and Rugolo M. Protection against oxidant-induced apoptosis by exogenous glutathione in Leber hereditary optic neuropathy cybrids. Invest Ophthalmol Vis Sci 49 (2008) 671-676
71. Hargreaves I.P., Sheena Y., Land J.M., and Heales S.J. Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis 28 (2005) 81-88
72. Kidd P.M. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev 10 (2005) 268-293
73. de Cavanagh E.M., Ferder L., Toblli J.E., Piotrkowski B., Stella I., Fraga C.G., et al. Renal mitochondrial impairment is attenuated by AT1 blockade in experimental type I diabetes. Am J Physiol Heart Circ Physiol 294 (2008) H456-H465
74. Neustadt J., and Pieczenik S.R. Medication-induced mitochondrial damage and disease. Mol Nutr Food Res 52 (2008) 780-788
75. Tauskela J.S. MitoQ - a mitochondria-targeted antioxidant. Drugs 10 (2007) 399-412
76. Mori M., Yamagata T., Goto T., Saito S., and Momoi M.Y. Dichloroacetate treatment for mitochondrial cytopathy: long-term effects in MELAS. Brain Dev 26 (2004) 453-458
77. Nakano K., Tarashima M., Tachikawa E., Noda N., Nakayama T., Sasaki K., et al. Platelet mitochondrial evaluation during cytochrome c and dichloroacetate treatments of MELAS. Mitochondrion 5 (2005) 426-433
78. Kaufmann P., Engelstad K., Wei Y., Jhung S., Sano M.C., Shungu D.C., et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 66 (2006) 324-330
79. Oishi K., Yoshioka M., Ozawa R., Yamamoto T., Oya Y., Ogawa M., et al. Dichloroacetate treatment for adult patients with mitochondrial disease. Rinsho Shinkeigaku 43 (2003) 154-161
80. Stacpoole P.W., Gilbert L.R., Neiberger R.E., Carney P.R., Valenstein E., Theriaque D.W., et al. Evaluation of long-term treatment of children with congenital lactic acidosis with dichloroacetate. Pediatrics 121 (2008) e1223-e1228
81. Angelini C., Federico A., Reichmann H., Lombes A., Chinnery P., and Turnbull D. Task force guidelines handbook: EFNS guidelines on diagnosis and management of fatty acid mitochondrial disorders. Eur J Neurol 13 (2006) 923-929
82. Tarnopolsky M.A., and Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med Sci Sports Exerc 37 (2005) 2086-2093
83. Bugiani M., Lamantea E., Invernizzi F., Moroni I., Bizzi A., Zeviani M., et al. Effects of riboflavin in children with complex II deficiency. Brain Dev 28 (2006) 576-581
84. Zafeiriou D.I., Augoustides-Savvopoulou P., Haas D., Smet J., Triantafyllou P., Vargiami E., et al. Ethylmalonic encephalopathy: clinical and biochemical observations. Neuropediatrics 38 (2007) 78-82
85. Oguro H., Iijima K., Takahashi K., Nagai A., Bokura H., Yamaguchi S., et al. Successful treatment with succinate in a patient with MELAS. Intern Med 43 (2004) 427-431
86. Tarnopolsky M.A., Roy B.D., and MacDonald J.R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20 (1997) 1502-1509
87. Komura K., Nakano K., Ishigaki K., Tarashima M., Nakayama T., Sasaki K., et al. Creatine monohydrate therapy in a Leigh syndrome patient with A8344G mutation. Pediatr Int 8 (2006) 409-412
88. Borchert A., Wilichowski E., and Hanefeld F. Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve 22 (1999) 1299-1300
89. Schols L., Zange J., Abele M., Schillings M., Skipka G., Kuntz-Hehner S., et al. L-carnitine and creatine in Friedreich's ataxia. A randomized, placebo-controlled crossover trial. J Neural Transm 112 (2005) 789-796
90. Kornblum C., Schröder R., Müller K., Vorgerd M., Eggers J., Bogdanow M., et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol 12 (2005) 300-309
91. Koga Y., Akita Y., Junko N., Yatsuga S., Povalko N., Fukiyama R., et al. Endothelial dysfunction in MELAS improved by L-arginine supplementation. Neurology 66 (2006) 1766-1769
92. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Tanabe Y., et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64 (2005) 710-712
93. Sproule DM, Dyme J, Coku J, de Vinck D, Rosenzweig E, Chung WK, et al. Pulmonary artery hypertension in a child with MELAS due to a point mutation of the mitochondrial tRNA((Leu)) gene (m.3243A>G). J Inherit Metab Dis 2008; (in press).
94. Toth G., Morava E., Bene J., Selhorst J.J., Overmars H., Vreken P., et al. Carnitine-responsive carnitine insufficiency in a case of mtDNA 8993T>C mutation associated Leigh syndrome. J Inherit Metab Dis 24 (2001) 421-422
95. Sato Y., Nakagawa M., Higuchi I., Osame M., Naito E., and Oizumi K. Mitochondrial myopathy and familial thiamine deficiency. Muscle Nerve 23 (2000) 1069-1075
96. Scharfe C., Hauschild M., Klopstock T., Janssen A.J., Heidemann P.H., Meitinger T., et al. A novel mutation in the thiamine responsive megaloblastic anaemia gene SLC19A2 in a patient with deficiency of respiratory chain complex I. J Med Genet 37 (2000) 669-673
97. Heller T., Hochstetter V., Basler M., and Borck V. Vitamin B6-sensitive hereditary sideroblastic anemia. Dtsch Med Wochenschr 129 (2004) 141-144
98. Shneyvays V., Leshem D., Shmist Y., Zinman T., and Shainberg A. Effects of menadione and its derivative on cultured cardiomyocytes with mitochondrial disorders. J Mol Cell Cardiol 39 (2005) 149-158
99. Ohinata J., Hasegawa T., and Kohyama J. A case of childhood onset myoclonus epilepsy with ragged-red fibers - with special reference to various clinical manifestations. No To Hattatsu 34 (2002) 427-430
100. Parini R., Furlan F., Notarangelo L., Spinazzola A., Uziel G., Strisciuglio P., et al. Glucose metabolism and diet-based prevention of liver dysfunction in MPV17 mutant patients. J Hepatol 50 (2009) 215-221
101. De Sanctis V., Calzolari F., Piazzi A., and Berio A. Kearns-Sayre syndrome associated with growth hormone deficiency. Pediatr Med Chir 25 (2003) 447-451
102. Newman N.J., Biousse V., David R., Bhatti M.T., Hamilton S.R., Farris B.K., et al. Prophylaxis for second eye involvement in Leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol 140 (2005) 407-415
103. Lee W.S., and Sokol R.J. Liver disease in mitochondrial disorders. Semin Liver Dis 27 (2007) 259-273
104. Scaglia F., and Northrop J.L. The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options. CNS Drugs 20 (2006) 443-464
105. Koga Y., Ishibashi M., Ueki I., Yatsuga S., Fukiyama R., Akita Y., et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 58 (2002) 827-828
106. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Katayama K., et al. MELAS and L-arginine therapy. Mitochondrion 7 (2007) 133-139
107. Nelson I., Bonne G., Degoul F., Marsac C., Ponsot G., and Lestienne P. Kearns-Sayre syndrome with sideroblastic anemia: molecular investigations. Neuropediatrics 23 (1992) 199-205
108. Man P.Y., Turnbull D.M., and Chinnery P.F. Leber hereditary optic neuropathy. J Med Genet 39 (2002) 162-169
109. Spacey S.D., Szczygielski B.I., Young S.P., Hukin J., Selby K., and Snutch T.P. Malaysian siblings with Friedreich ataxia and chorea: a novel deletion in the frataxin gene. Can J Neurol Sci 31 (2004) 383-386
110. Campanella A., Isaya G., O'Neill H.A., Santambrogio P., Cozzi A., Arosio P., et al. The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeast. Hum Mol Genet 13 (2004) 2279-2288
111. Schapira A.H.V. The "new" mitochondrial disorders. J Neurol Neurosurg Psychiatry 72 (2002) 144-149
112. Fleming M.D. The genetics of inherited sideroblastic anemias. Semin Hematol 39 (2002) 270-281
113. Finsterer J. MELAS syndrome as a differential diagnosis of ischemic stroke. Fortschr Neurol Psychiatr 77 (2009) 25-31
114. Iizuka T., Sakai F., Ide T., Miyakawa S., Sato M., and Yoshii S. Regional cerebral blood flow and cerebrovascular reactivity during chronic stage of stroke-like episodes in MELAS - implication of neurovascular cellular mechanism. J Neurol Sci 257 (2007) 126-138
115. Panetta J., Smith L.J., and Boneh A. Effect of high-dose vitamins, coenzyme Q and high-fat diet in paediatric patients with mitochondrial diseases. J Inherit Metab Dis 27 (2004) 487-498
116. Marriage B.J., Clandinin M.T., Macdonald I.M., and Glerum D.M. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol Genet Metab 81 (2004) 263-272
117. Walker U.A. Mitochondrial medicine for internists. Med Klin (Munich) 95 (2000) 689-696
118. Walker U.A. Inherited and acquired disorders of mitochondrial DNA. Schweiz Rundsch Med Prax 91 (2002) 2129-2138
119. Adachi K., Fujiura Y., Mayumi F., Nozuhara A., Sugiu Y., Sakanashi T., et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun 195 (1993) 945-951
120. Gordon N. Alpers syndrome: progressive neuronal degeneration of children with liver disease. Dev Med Child Neurol 48 (2006) 1001-1003
121. Cocco T., Cutecchia G., Montedoro G., and Lorusso M. The antihypertensive drug carvedilol inhibits the activity of mitochondrial NADH-ubiquinone oxidoreductase. J Bioenerg Biomembr 34 (2002) 251-258
122. Finsterer J., Haberler C., and Schmiedel J. Deterioration of Kearns-Sayre syndrome following articaine administration for local anesthesia. Clin Neuropharmacol 28 (2005) 148-149
123. Sztark F., Payen J.F., Piriou V., Rigoulet M., Ventura-Clapier R., Mazat J.P., et al. Cellular energy metabolism: physiologic and pathologic aspects. Ann Fr Anesth Reanim 18 (1999) 261-269
124. Wei Y.H., Lin T.N., Hong C.Y., and Chiang B.N. Inhibition of the mitochondrial Mg2+-ATPase by propranolol. Biochem Pharmacol 1 34 (1985) 911-917
125. Riess M.L., Eells J.T., Kevin L.G., Camara A.K., Henry M.M., and Stowe D.F. Attenuation of mitochondrial respiration by sevoflurane in isolated cardiac mitochondria is mediated in part by reactive oxygen species. Anesthesiology 100 (2004) 498-505
126. Riess M.L., Kevin L.G., McCormick J., Jiang M.T., Rhodes S.S., and Stowe D.F. Anesthetic preconditioning: the role of free radicals in sevoflurane-induced attenuation of mitochondrial electron transport in guinea pig isolated hearts. Anesth Analg 100 (2005) 46-53
127. Finsterer J. Mitochondriopathies. Eur J Neurol 11 (2004) 163-186
128. Ascensão A., Magalhães J., Soares J.M., Ferreira R., Neuparth M.J., Marques F., et al. Moderate endurance training prevents doxorubicin-induced in vivo mitochondriopathy and reduces the development of cardiac apoptosis. Am J Physiol Heart Circ Physiol 289 (2005) H722-H731
129. Silva M.F., Ruiter J.P., Illst L., Jakobs C., Duran M., de Almeida I.T., et al. Valproate inhibits the mitochondrial pyruvate-driven oxidative phosphorylation in vitro. J Inherit Metab Dis 20 (1997) 397-400
130. Spinazzola A., Marti R., Nishino I., Andreu A.L., Naini A., Tadesse S., et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem 277 (2002) 4128-4133
131. Becerra E.M., Blanco G., Muiños Y., and Bianciotto C. Surgical treatment of acquired myogenic eyelid ptosis. Arch Soc Esp Oftalmol 80 (2005) 359-364
132. Milbrandt T.A., Kunes J.R., and Karol L.A. Friedreich's ataxia and scoliosis: the experience at two institutions. J Pediatr Orthop 28 (2008) 234-238
133. Sue C.M., Lipsett L.J., Crimmins D.S., Tsang C.S., Boyages S.C., Presgrave C.M., et al. Cochlear origin of hearing loss in MELAS syndrome. Ann Neurol 43 (1998) 350-359
134. Engelmann G., Meyburg J., Shahbek N., Al-Ali M., Hairetis M.H., Baker A.J., et al. Recurrent acute liver failure and mitochondriopathy in a case of Wolcott-Rallison syndrome. J Inherit Metab Dis 31 (2008) 540-546
135. Klepper J., Leiendecker B., Riemann E., and Baumeister F.A. The ketogenic diet in German-speaking countries: update 2003. Klin Padiatr 216 (2004) 277-285
136. Mochel F., DeLonlay P., Touati G., Brunengraber H., Kinman R.P., Rabier D., et al. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 84 (2005) 305-312
137. Cejudo P., Bautista J., Montemayor T., Villagómez R., Jiménez L., Ortega F., et al. Exercise training in mitochondrial myopathy: a randomized controlled trial. Muscle Nerve 32 (2005) 342-350
138. Taivassalo T., and Haller R.G. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 37 (2005) 2094-2101
139. Testa M., Navazio F.M., and Neugebauer J. Recognition, diagnosis, and treatment of mitochondrial myopathies in endurance athletes. Curr Sports Med Rep 4 (2005) 282-287
140. Sasano N., Fujita Y., So M., Sobue K., Sasano H., and Katsuya H. Anesthetic management of a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) during laparotomy. J Anesth 21 (2007) 72-75
141. Lara M.C., Weiss B., Illa I., Madoz P., Massuet L., Andreu A.L., et al. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 67 (2006) 1461-1463
142. Lara M.C., Valentino M.L., Torres-Torronteras J., Hirano M., and Martí R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep 27 (2007) 151-163
143. Bonnet C., Kaltimbacher V., Ellouze S., Augustin S., Bénit P., Forster V., et al. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or V subunits. Rejuvenation Res 10 (2007) 127-144
144. DiMauro S., Mancuso M., and Naini A. Mitochondrial encephalomyopathies: therapeutic approach. Ann N Y Acad Sci 1011 (2004) 232-245
145. Murphy J.L., Blakely E.L., Schaefer A.M., He L., Wyrick P., Haller R.G., et al. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 131 (2008) 2832-2840
146. Bachmann R.F., Wang Y., Yuan P., Zhou R., Li X., Alesci S., et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 12 (2009) 1-18
147. Leo S., Szabadkai G., and Rizzuto R. The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle. Ann N Y Acad Sci 1147 (2008) 264-274
148. Szeto H.H. Development of mitochondria-targeted aromatic-cationic peptides for neurodegenerative diseases. Ann N Y Acad Sci 1147 (2008) 112-121
149. Murphy M.P. Development of lipophilic cations as therapies for disorders due to mitochondrial dysfunction. Expert Opin Biol Ther 1 (2001) 753-764
150. Smith R.A., Adlam V.J., Blaikie F.H., Manas A.R., Porteous C.M., James A.M., et al. Mitochondria-targeted antioxidants in the treatment of disease. Ann N Y Acad Sci 1147 (2008) 105-111
151. Ajith T.A., Sudheesh N.P., Roshny D., Abishek G., and Janardhanan K.K. Effect of Ganoderma lucidum on the activities of mitochondrial dehydrogenases and complex I and II of electron transport chain in the brain of aged rats. Exp Gerontol Exp Gerontol 44 (2009) 219-223
152. Rojas J.C., Lee J., John J.M., and Gonzalez-Lima F. Neuroprotective effects of near-infrared light in an in vivo model of mitochondrial optic neuropathy. J Neurosci 28 (2008) 13511-13521
153. Kariya S., Hirano M., Furiya Y., and Ueno S. Effect of humanin on decreased ATP levels of human lymphocytes harboring A3243G mutant mitochondrial DNA. Neuropeptides 39 (2005) 97-101
154. Leon J., Acuña-Castroviejo D., Sainz R.M., Mayo J.C., Tan D.X., and Reiter R.J. Melatonin and mitochondrial function. Life Sci 75 (2004) 765-790
155. Guha M., Maity P., Choubey V., Mitra K., Reiter R.J., and Bandyopadhyay U. Melatonin inhibits free radical-mediated mitochondrial-dependent hepatocyte apoptosis and liver damage induced during malarial infection. J Pineal Res 43 (2007) 372-381
156. Lin C.H., Huang J.Y., Ching C.H., and Chuang J.I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 44 (2008) 205-213
157. Murphy M.P. Targeting lipophilic cations to mitochondria. Biochim Biophys Acta 1777 (2008) 1028-1031
158. Chinnery P., Majamaa K., Turnbull D., and Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev (2006) (1): CD004426